Marizyme Stock Market Value
| MRZM Stock | USD 0.05 0.01 25.00% |
| Symbol | Marizyme |
Marizyme 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Marizyme's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Marizyme.
| 10/31/2024 |
| 11/30/2024 |
If you would invest 0.00 in Marizyme on October 31, 2024 and sell it all today you would earn a total of 0.00 from holding Marizyme or generate 0.0% return on investment in Marizyme over 30 days. Marizyme is related to or competes with Aerovate Therapeutics, Akari Therapeutics, Armata Pharmaceuticals, Anebulo Pharmaceuticals, Processa Pharmaceuticals, Inhibikase Therapeutics, and Tempest Therapeutics. Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies busines... More
Marizyme Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Marizyme's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Marizyme upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 33.55 | |||
| Information Ratio | 0.1152 | |||
| Maximum Drawdown | 128.57 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 50.0 |
Marizyme Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marizyme's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Marizyme's standard deviation. In reality, there are many statistical measures that can use Marizyme historical prices to predict the future Marizyme's volatility.| Risk Adjusted Performance | 0.1027 | |||
| Jensen Alpha | 2.77 | |||
| Total Risk Alpha | (0.96) | |||
| Sortino Ratio | 0.0726 | |||
| Treynor Ratio | (1.57) |
Marizyme Backtested Returns
Marizyme is out of control given 3 months investment horizon. Marizyme has Sharpe Ratio of 0.0986, which conveys that the firm had a 0.0986% return per unit of risk over the last 3 months. We were able to analyze twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.95% are justified by taking the suggested risk. Use Marizyme Mean Deviation of 9.89, downside deviation of 33.55, and Risk Adjusted Performance of 0.1027 to evaluate company specific risk that cannot be diversified away. Marizyme holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -1.63, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Marizyme are expected to decrease by larger amounts. On the other hand, during market turmoil, Marizyme is expected to outperform it. Use Marizyme potential upside, as well as the relationship between the daily balance of power and relative strength index , to analyze future returns on Marizyme.
Auto-correlation | -0.29 |
Weak reverse predictability
Marizyme has weak reverse predictability. Overlapping area represents the amount of predictability between Marizyme time series from 31st of October 2024 to 15th of November 2024 and 15th of November 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Marizyme price movement. The serial correlation of -0.29 indicates that nearly 29.0% of current Marizyme price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.29 | |
| Spearman Rank Test | 0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Marizyme lagged returns against current returns
Autocorrelation, which is Marizyme otc stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Marizyme's otc stock expected returns. We can calculate the autocorrelation of Marizyme returns to help us make a trade decision. For example, suppose you find that Marizyme has exhibited high autocorrelation historically, and you observe that the otc stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Marizyme regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Marizyme otc stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Marizyme otc stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Marizyme otc stock over time.
Current vs Lagged Prices |
| Timeline |
Marizyme Lagged Returns
When evaluating Marizyme's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Marizyme otc stock have on its future price. Marizyme autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Marizyme autocorrelation shows the relationship between Marizyme otc stock current value and its past values and can show if there is a momentum factor associated with investing in Marizyme.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.